Precipio (PRPO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Proxy statement filed for annual meeting, including voting on key corporate matters.
Voting matters and shareholder proposals
Shareholders to vote on director elections and other significant proposals.
Shareholder rights and capital structure
No filing fee required, indicating no material change to capital structure.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Precipio
- Q2 2025 net sales up 27%, gross margin at 43%, with positive net income but ongoing risks.PRPO
Q2 202527 Jan 2026 - Q1 2025 revenue up 44% to $4.9M, gross margin 43%, net loss narrowed, but risks remain.PRPOQ1 202527 Jan 2026
- Q3 2025 saw 30% revenue growth, positive EBITDA, 44% margin, but going concern risk persists.PRPOQ3 202527 Jan 2026
- Net sales and pathology revenues rose, but losses and liquidity concerns remain.PRPOQ3 202427 Jan 2026
- Q2 2024 revenue up 26% to $4.4M, losses narrowed, but going concern risks remain.PRPOQ2 202427 Jan 2026
- Achieved Q4 break-even, strong revenue growth, and set ambitious 2025 expansion targets.PRPOQ4 202426 Dec 2025
- Annual meeting to elect directors, ratify auditor, and highlight board independence and ESG.PRPOProxy Filing1 Dec 2025
- Shareholders must vote promptly to ensure quorum and avoid costly meeting delays.PRPOProxy Filing1 Dec 2025
- Shareholder votes needed by 11 p.m. ET to avoid costly adjournment of annual meeting.PRPOProxy Filing1 Dec 2025